Monday, August 11, 2014

Depressed? Botox just might help you feel better

Nothing helped with her debilitating depression. Not massage therapy, not physical therapy and not aqua therapy. And then, Vivian Cooke found Botox.
Several times a year, Cooke receives an injection of the drug — best known for smoothing out facial wrinkles by paralyzing muscles or blocking nerves — between her eyebrows to help with depression.
“This is an alternative for me that has proven to be, almost immediately, giving the result that I want, and that is to feel happier and not be depressed,” Cooke told TODAY.

Check out the rest of this article and a clip here
http://www.today.com/health/depressed-botox-just-might-help-you-feel-better-1D79912948

Friday, August 8, 2014

How Young Is Too Young for Botox?

How Young Is Too Young for Botox?

by Morgan Korn

You probably know someone who has been injected with Botox – and you might be surprised by how young they are.
Botox has become the most popular cosmetic treatment in the United States, accounting for 3.77 million of the 5.89 million injectable procedures performed in 2013, according to a survey conducted by the American Society for Aesthetic Plastic Surgery (ASAPS). And that number keeps rising: Injectable procedures were up nearly 16 percent last year compared with 2012.
The demand for Botox has become so strong that many doctors who are not plastic surgeons are now trained in the practice. But the concerns surrounding Botox have shifted in recent years from safety to the increasingly younger ages at which women are seeking injections. Women in their mid-to-late 20s are increasingly turning to Botox to prevent the onset of wrinkles. And men are too, actually: The number of cosmetic procedures for males rose 22 percent from 2000 through 2012, according to the American Society of Plastic Surgeons. 
Botox – a drug made from a neurotoxin produced by the bacterium clostridium botulinum, the same toxin causes a life-threatening type of food poisoning called botulism – works by blocking signals from the nerves to the muscles. Areas injected with Botox, or competitors like Dysport and Xeomin, become weakened or temporarily paralyzed, and the effect relaxes and softens facial wrinkles for an average of three to four months.
The appeal of Botox might be understandable for older women eager to hide signs of aging, but why would a 21-year-old be interested in such a procedure? Michael Edwards, MD, president of ASAPS, says celebrities’ obsession with Botox has raised its profile with teens and young women. Kim Kardashian, for example, admitted to trying Botox in 2010, at the age of 29.
“We’re seeing younger and younger people doing it,” he explains. “It’s not uncommon to have 22- and 23-year-olds getting Botox.”
Young people ages 19 to 34 underwent more than 546,000 Botox procedures last year, an 11.7 percent increase from 2012 and a 36 percent rise from 2010. To compare, those between 35 and 50 underwent 1.72 million Botox procedures in 2013, while teens 18 and younger got 1,149 procedures. Edwards says he would not accept Botox patients who are under the age of 18 unless that individual had parental consent. 
And while he has talked young women out of Botox, he will inject some younger individuals if the circumstances warrant it. “If it’s a healthy young person with an animated face I’ll happily do it,” he says. “I see a lot of young people with wrinkles.”
The FDA has approved Botox for 10 uses in the United States. The list includes crow’s feet, frown lines (wrinkles between the eyebrows), crossed eyes, uncontrollable blinking, chronic migraines, neck spasms, and excessive sweating, while injections in the forehead and around the corners of the mouth are not scientifically authorized by the government agency and performed “off label.”
New York-based plastic surgeon Doris Day, MD, says she has injected an 18-year-old patient with Botox. That particular patient had a “strong crease” across her forehead and it was more of a “medical than aesthetic” decision, Day explains. The Botox “took the edge off” and the young woman has continued with yearly injections for the last five years, according to Day. In general, Day – who has been practicing cosmetic dermatology in New York for more than 15 years – does not ask a patient for his or her age before treatment, but emphasizes that 17- and 18-year-olds asking for Botox are “misguided” and cautions that Botox “is not a spa treatment.”
According to Botox maker Allergan, the injectable was “approved in the United States in 2002 for the temporary improvement of moderate to severe glabellar lines (frown lines between the brows) for patients aged 18 to 65 years.”
Day suggests that young adults who want to age “successfully” focus on their skincare regime first before turning to Botox. That means wearing sunscreen on a daily basis, sleeping eight hours each night, and applying topical retinol and antioxidant creams and serums. She also educates individuals about “correct” facial postures – how to smile from the eyes and not the mouth, for instance – and “neutralizing” expressions that tend to breakdown collagen from repetition (like squinting and frowning).
Young adults, she insists, tend to forget one very important aspect of Botox: It’s not a wrinkle cure-all.
“Young people have this attitude that we can ‘laser it, fill it, Botox it’,” she says. “[Botox] can only repair so much.”
original article here
https://www.yahoo.com/health/how-young-is-too-young-for-botox-91917811907.html

Thursday, August 7, 2014

Galderma to gain rights to Restylane, Perlane, Sculptra and Dysport in the United States and Canada

MAY 29, 2014
  • Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in
    the U.S. and Canada
  • Galderma reinforces long‐term commitment to meet physician and patient needs in aesthetic and corrective dermatology worldwide
Fort Worth, Texas (May 28, 2014) – Galderma Laboratories, L.P. (“Galderma”) announced today that Nestlé S.A., Switzerland, one of Galderma’s shareholders, has entered into an agreement with Valeant Pharmaceuticals International, Inc. and related entities (“Valeant”), through which Galderma will become the distributor of several key products in aesthetic dermatology. Galderma will gain full rights to
commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.

Humberto C. Antunes, President & CEO of Galderma worldwide, based in Lausanne, Switzerland, expressed, “We are very grateful that Nestlé has continued to support Galderma through this transaction. The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness. Thanks to this agreement with Valeant,
Galderma will be able to provide this best‐in‐class portfolio of fillers and muscle relaxant for aesthetic and corrective dermatology also in the United States and Canada.”

Stuart Raetzman, CEO of Galderma Laboratories, L.P. and Galderma North America, said from Fort Worth, Texas, “This further marks the commitment of Galderma employees in the United States and Canada to aesthetic and corrective dermatology. We all work together to maintain the industry’s highest standards of clinical safety and efficacy, to bring a wide range of scientifically advanced and clinically proven medical solutions to physicians. Our portfolio of products, combined with exclusive services and medical training programs, positions Galderma as the preferred partner of dermatologists, plastic surgeons and aesthetic physicians.”

Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre‐existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these innovative and leading brands globally.
Sculptra is owned by Valeant. Through this transaction Galderma is acquiring this product and will commercialize it in the U.S. and Canada and select other markets around the world.

Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. Through this transaction, Galderma will gain the right to commercialize Dysport for aesthetic dermatology indications in the U.S. and Canada.

This transaction is also subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisors, and Debevoise and Plimpton as legal advisors to Galderma.

In February 2014, Nestlé announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oréal. The transaction between Nestlé and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.
see original article here 
http://www.galderma.com/News/articleType/ArticleView/articleId/59/Galderma-to-gain-rights-to-Restylane-Perlane-Sculptra-and-Dysport-in-the-United-States-and-Canada